SEC and FDA Sign MOU to Bolster Cooperation and Market Integrity

This inter-agency pact signals a regulatory alignment that could blur the lines between securities oversight and health-product compliance, potentially creating new compliance touchpoints for companies straddling both domains—such as those in biotech or digital health with tokenized assets. The lack of disclosed specifics leaves the practical impact unclear, but the formalized coordination suggests a more integrated enforcement posture ahead. The open question is whether this MOU will lead to joint investigations or rulemaking that reshapes disclosure duties for regulated entities.